What is VisiRose?
VisiRose operates at the intersection of biotechnology and ophthalmology, functioning as a specialized entity born from the collaborative efforts of the University of Miami and Provectus Biopharmaceuticals. The company is primarily tasked with the commercialization of groundbreaking ocular research originating from the Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center. By leveraging bioactive synthetic small molecule rose bengal, VisiRose aims to address significant unmet needs in eye care, positioning itself as a high-authority player in the ophthalmic therapeutics sector. The firm's core focus remains the translation of complex biophysical research into scalable, patient-centric medical solutions.
How much funding has VisiRose raised?
VisiRose has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2025): $3M with participation from Provectus Biopharmaceuticals
Key Investors in VisiRose
Provectus Biopharmaceuticals
Provectus Biopharmaceuticals is a clinical-stage biotechnology firm specializing in the development of halogenated xanthene-based immunotherapy medicines for oncology, dermatology, and ophthalmology.
What's next for VisiRose?
With this major enterprise-level funding, VisiRose is poised to enter a critical phase of operational scaling and clinical validation. The strategic roadmap involves refining the delivery mechanisms for its rose bengal-based therapies and navigating the regulatory landscape to bring these innovations to market. By maintaining its strong ties to academic research while utilizing the commercial expertise of its partners, VisiRose is set to disrupt traditional ophthalmic treatment paradigms. Future growth will likely center on expanding its intellectual property portfolio and establishing robust clinical trial frameworks to demonstrate the efficacy of its synthetic small molecule platform in diverse patient populations.
See full VisiRose company page
